PURPOSE: Most node-negative breast cancer patients are older and postmenopausal and are increasingly being offered adjuvant chemotherapy despite their low overall risk of distant relapse. A molecular diagnostic test with high negative predictive value (NPV) for distant metastasis in this subgroup would spare many older breast cancer patients adjuvant treatment. EXPERIMENTAL DESIGN: We determined the NPV and positive predictive value of the MammaPrint assay in breast cancer patients who were consecutively diagnosed and treated at the Massachusetts General Hospital between 1985 and 1997. Primary tumors from 100 patients with node-negative, invasive breast cancer (median age, 62.5 years; median follow-up, 11.3 years) were subjected to MammaPrint analysis and classified as being at either low or high risk for distant metastasis. RESULTS: The MammaPrint 70-gene signature displayed excellent NPV as in previous studies, correctly identifying 100% of women at low risk for distant metastases at 5 years. However, this assay had a lower positive predictive value (12% at 5 years) than previously observed. CONCLUSIONS: The MammaPrint assay was originally designed to identify younger breast cancer patients at low risk for distant metastasis, who might consequently be spared systemic treatment. We show here that the same signature has a very high NPV for distant recurrence after adjuvant treatment in older breast cancer patients.
PURPOSE: Most node-negative breast cancerpatients are older and postmenopausal and are increasingly being offered adjuvant chemotherapy despite their low overall risk of distant relapse. A molecular diagnostic test with high negative predictive value (NPV) for distant metastasis in this subgroup would spare many older breast cancerpatients adjuvant treatment. EXPERIMENTAL DESIGN: We determined the NPV and positive predictive value of the MammaPrint assay in breast cancerpatients who were consecutively diagnosed and treated at the Massachusetts General Hospital between 1985 and 1997. Primary tumors from 100 patients with node-negative, invasive breast cancer (median age, 62.5 years; median follow-up, 11.3 years) were subjected to MammaPrint analysis and classified as being at either low or high risk for distant metastasis. RESULTS: The MammaPrint 70-gene signature displayed excellent NPV as in previous studies, correctly identifying 100% of women at low risk for distant metastases at 5 years. However, this assay had a lower positive predictive value (12% at 5 years) than previously observed. CONCLUSIONS: The MammaPrint assay was originally designed to identify younger breast cancerpatients at low risk for distant metastasis, who might consequently be spared systemic treatment. We show here that the same signature has a very high NPV for distant recurrence after adjuvant treatment in older breast cancerpatients.
Authors: P Eifel; J A Axelson; J Costa; J Crowley; W J Curran; A Deshler; S Fulton; C B Hendricks; M Kemeny; A B Kornblith; T A Louis; M Markman; R Mayer; D Roter Journal: J Natl Cancer Inst Date: 2001-07-04 Impact factor: 13.506
Authors: Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Annuska M Glas; Arno Floore; Leonie J M J Delahaye; Anke T Witteveen; Rob C F Pover; Niels Bakx; Jaana S T Lahti-Domenici; Tako J Bruinsma; Marc O Warmoes; René Bernards; Lodewyk F A Wessels; Laura J Van't Veer Journal: BMC Genomics Date: 2006-10-30 Impact factor: 3.969
Authors: Xiao-Jun Ma; Zuncai Wang; Paula D Ryan; Steven J Isakoff; Anne Barmettler; Andrew Fuller; Beth Muir; Gayatry Mohapatra; Ranelle Salunga; J Todd Tuggle; Yen Tran; Diem Tran; Ana Tassin; Paul Amon; Wilson Wang; Wei Wang; Edward Enright; Kimberly Stecker; Eden Estepa-Sabal; Barbara Smith; Jerry Younger; Ulysses Balis; James Michaelson; Atul Bhan; Karleen Habin; Thomas M Baer; Joan Brugge; Daniel A Haber; Mark G Erlander; Dennis C Sgroi Journal: Cancer Cell Date: 2004-06 Impact factor: 31.743
Authors: Jon Whitney; German Corredor; Andrew Janowczyk; Shridar Ganesan; Scott Doyle; John Tomaszewski; Michael Feldman; Hannah Gilmore; Anant Madabhushi Journal: BMC Cancer Date: 2018-05-30 Impact factor: 4.430
Authors: P Sinn; S Aulmann; R Wirtz; S Schott; F Marmé; Z Varga; A Lebeau; H Kreipe; A Schneeweiss Journal: Geburtshilfe Frauenheilkd Date: 2013-09 Impact factor: 2.915